Autologous versus allogeneic: how cell therapy development is changing in oncology
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
Immuno
SLE and LN market expected to reach $5.9bn across 7MM by 2034
Sensei to ditch its lead candidate and cut workforce amidst strategic review
Teva to collaborate with Fosun Pharma for TEV-56278
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
NICE approves GSK’s belantamab mafodotin for blood cancer
Antares Therapeutics gains $177m for cancer medicines development
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
